Otonomy, Inc.

University of California

Novartis Ag

Nektar Therapeutics

Samumed, LLC

Alliance Pharmaceutical Corp.

Biosplice Therapeutics, Inc.

Inhale Therapeutic Systems, Inc.

Other

Novartis Pharma Ag

Endeavor Biomedicines, Inc.

Domp&#xe9; Farmaceutici S.p.a.

Regents of the Univeristy of California

Alk-abell&#xd3;, Inc.

Multicell Immunotherapeutics, Inc.

Luis A Dellamary

Qiang Ye

Fabrice Piu

Carl Lebel

Jay Lichter

Andrew M Trammel

Jeffrey P Harris

Thomas E Tarara

Jeffry G Weers

Ernest George Schutt

Alexey S Kabalnov

Benedikt K Vollrath

Michael Christopher Scaife

Sergio G Duron

John Hood

Jean G Riess

Sunil Kumar Kc

David Mark Wallace

Yusuf Yazici

Christopher Swearingen

Sergio G Durón

Leo A Trevino

Miguel De Los Rios

Anita Difrancesco

Helen M Ranney

Adrian I Bot

Dan Joseph Smith

Lorraine E Reeve

Adrian Ion Bot

Marie-Pierre Krafft

Stephen G Flore

Alexev Kabalnov

William Joseph Phillips, Jr

Lilin Wang

Jean Reiss

Jeffrey G Weers

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

Methods of treating fibrosis

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.

Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

Auris formulations for treating otic diseases and conditions

Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.

Single-dose, ready-to-use injectable formulations

Indazole compounds for treating various diseases and pathologies are provided. More particularly, the use of an indazole compound or analogs thereof, in the treatment of inflammatory diseases or disorders is provided.

2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof

Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.

Treatment of osteoarthritis

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Controlled release antimicrobial compositions and methods for the treatment of otic disorders

Auris formulations for treating OTIC diseases and conditions

Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Controlled-release CNS modulating compositions and methods for the treatment of otic disorders

Growing community of inventors

San Marcos, CA, United States of America

Luis A Dellamary